Measurement of blood levels of imatinib to predict early response to treatment in patients with chronic myeloid leukemia
Not Applicable
Completed
- Conditions
- Health Condition 1: null- Chronic Myeloid Leukemia
- Registration Number
- CTRI/2018/01/011356
- Lead Sponsor
- Tata Memorial Hospital Mumbai
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 52
Inclusion Criteria
Chronic Myeloid Leukemia in chronic phase
Age more than 18 years
Exclusion Criteria
1. Patients on concurrent medications affecting imatinib drug levels
2. Patients who have been priorly treated outside with Imatinib before referral to our institute
3. Patients in whom compliance is not assured
4. Patients in accelerated phase or blast crisis of chronic myeloid leukemia as per the WHO definition
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Correlation of trough plasma imatinib levels with three month molecular responsesTimepoint: 3 months
- Secondary Outcome Measures
Name Time Method Correlation of trough plasma imatinib levels with three month molecular responsesTimepoint: 6 months